{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:06:09Z","timestamp":1782515169970,"version":"3.54.5"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,12,28]],"date-time":"2009-12-28T00:00:00Z","timestamp":1261958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy and safety of terguride, a partial dopamine agonist, in patients with fibromyalgia syndrome (FMS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a 12\u2010week, multicenter, double\u2010blind, placebo\u2010controlled, parallel\u2010group study, 99 patients were randomized at a ratio of 2 to 1 to receive terguride or placebo. Over 21 days, the dosage was titrated to a maximum daily dose of 3 mg of terguride or placebo, and this fixed dosage was continued over 9 weeks. The primary efficacy variable was the intensity of pain (100\u2010mm visual analog scale). Secondary efficacy variables included the Fibromyalgia Impact Questionnaire (FIQ) score, the tender point score (TPS), and the Hamilton Depression Scale (HDS) score. During the study, patients were evaluated for the presence of cervical spine stenosis by magnetic resonance imaging (MRI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant differences in the change in pain intensity, FIQ score, TPS, or HDS score between baseline and 12 weeks were observed in the terguride group as compared with the placebo group. Cervical spine stenosis was detected in 22% of the patients. Only patients with cervical spine stenosis responded to terguride treatment. FIQ scores improved significantly (per\u2010protocol analysis), and pain intensity, the TPS score, and the HDS score showed a trend toward improvement in the terguride group as compared with the placebo group. Terguride treatment was safe. Only those adverse events already known to be side effects of terguride were observed. Premature termination of the study in patients receiving terguride (26%) occurred predominantly during up\u2010titration and in the absence of comedication for treatment of nausea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Terguride treatment did not improve pain, the FIQ score, the TPS, or the HDS score in the total study population. However, a subgroup of patients with cervical spine stenosis seemed to benefit from terguride treatment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.25062","type":"journal-article","created":{"date-parts":[[2009,12,28]],"date-time":"2009-12-28T21:07:06Z","timestamp":1262034426000},"page":"291-300","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve\u2010week, multicenter, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study"],"prefix":"10.1002","volume":"62","author":[{"given":"Oliver","family":"Distler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Dvorak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Gaubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan\u2010Peter","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Pache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller\u2010Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(96)03188-0"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.03.007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-002-0046-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208799316348"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097400446599"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(03)00030-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371106"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.3.290"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.5.781"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2003.10.013"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2007.05623.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.05.014"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.07.024"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00298-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00009-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21191"},{"key":"e_1_2_6_19_2","unstructured":"GlaxoSmithKline Result Summary for ROF102100. A randomised double\u2010blind placebo\u2010controlled parallel group study to investigate the safety and efficacy of controlled\u2010release ropinirole (CR) (1\u201324 mg) administered once daily for 12 weeks in subjects with fibromyalgia. URL:http:\/\/www.gsk\u2010clinicalstudyregister.com\/files\/pdf\/21016.pdf."},{"key":"e_1_2_6_20_2","unstructured":"Clinical Trials.gov. A double\u2010blind multicenter proof of concept trial to assess the efficacy and safety of rotigotine in subjects with fibromyalgia syndrome (SP888). URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00464737?term=rotigotine&rank=8."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_6_22_2","first-page":"288","article-title":"Terguride","volume":"11","author":"Riederer P","year":"1986","journal-title":"Drugs Future"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651060-00004"},{"key":"e_1_2_6_24_2","first-page":"768","article-title":"Measurement of pain","volume":"9","author":"Huskisson EC","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310205"},{"key":"e_1_2_6_26_2","first-page":"728","article-title":"The Fibromyalgia Impact Questionnaire: development and validation","volume":"18","author":"Burckhardt CS","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"e_1_2_6_28_2","first-page":"1763","article-title":"Classification system based on kinematic MR imaging in cervical spondylitic myelopathy","volume":"19","author":"Muhle C","year":"1998","journal-title":"AJNR Am J Neuroradiol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1300\/J094v12n01_04"},{"key":"e_1_2_6_30_2","first-page":"573","article-title":"Terguride: partial dopamine agonist in the treatment of Parkinson's disease","volume":"45","author":"Brucke T","year":"1987","journal-title":"Adv Neurol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(03)00165-5"},{"key":"e_1_2_6_32_2","unstructured":"UCB. UCB announces top\u2010line outcomes for proof\u2010of\u2010concept studies. URL:www.ucb.com\/media\u2010room\/newsdetail\/?det=1292262&select\u2010year=all&select\u2010archive=ucb."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90794-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e32813c5462"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039875"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-004-0672-x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.01.339"},{"key":"e_1_2_6_38_2","first-page":"S173","article-title":"Prevalence of Chiari malformation, and cervical stenosis, in fibromyalgia","volume":"43","author":"Clauw DJ","year":"2000","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200205000-00006"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2003.05.001"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbmt.2004.12.003"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.29.4.315"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3181753c1e"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.3171\/spi.2005.2.4.0441"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000253601.35732.c1"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-007-0534-4"},{"key":"e_1_2_6_47_2","unstructured":"GornemannT. Derivatives of pergolide lisuride and terguride as ligands for serotonergic adrenergic and dopaminergic receptors [dissertation]. Berlin: Freie Universit\u00e4t Berlin;2008. URL:www.diss.fu\u2010berlin.de\/diss\/receive\/FUDISS_thesis_000000004029. In German."},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.6.662"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00637669"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1483"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.25062","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.25062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:12:04Z","timestamp":1700752324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.25062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/art.25062"],"URL":"https:\/\/doi.org\/10.1002\/art.25062","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,28]]}}}